The potential of viral vector-mediated gene transfer to prolong corneal allograft survival

Current Gene Therapy

Volumn 9, Issue 1, 2009, Pages 33-44

  Parker, Douglas G A ^a   Brereton, Helen M ^a   Coster, Douglas J ^a   Williams, Keryn A ^a,b  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Adeno associated viral vector; Adenoviral vector; Corneal endothelium; Corneal transplantation; Graft rejection; Immunogenicity; Lentiviral vector; Transgene

Indexed keywords

ABATACEPT; ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 12; INTERLEUKIN 4; LENTIVIRUS VECTOR; MACROPHAGE INFLAMMATORY PROTEIN 2; NERVE GROWTH FACTOR; PROTEIN P40; RECOMBINANT INTERLEUKIN 10; TUMOR NECROSIS FACTOR RECEPTOR; VIRUS VECTOR;

CORNEA TRANSPLANTATION; DRUG SAFETY; EX VIVO GENE TRANSFER; EXPERIMENTAL TRANSPLANTATION; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; GENE TARGETING; GENE TRANSFER; GENETIC TRANSDUCTION; GRAFT SURVIVAL; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; REVIEW; SURVIVAL TIME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ADENOVIRUS; ALLOTRANSPLANTATION; CORNEA DISEASE; GENE THERAPY; GENE VECTOR; GENETICS; GRAFT REJECTION; IMMUNOLOGY; PHYSIOLOGY;

ANIMALIA;

ADENOVIRIDAE; CORNEAL DISEASES; CORNEAL TRANSPLANTATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; TRANSPLANTATION, HOMOLOGOUS;

EID: 65349179021     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652309787354621     Document Type: Review

References (102)

1. George AJ, Larkin DF. Corneal transplantation: the forgotten graft. Am J Transplant 2004; 4: 678-85.
2. Williams KA, Coster DJ. The immunobiology of corneal transplantation. Transplantation 2007; 84: 806-13.
3. Jun AS, Larkin DF. Prospects for gene therapy in corneal disease. Eye 2003; 17: 906-11.
4. Williams KA, Jessup CF, Coster DJ. Gene therapy approaches to prolonging corneal allograft survival. Expert Opin Biol Ther 2004; 4: 1059-71.
5. Mohan RR, Sharma A, Netto MV, Sinha S, Wilson SE. Gene therapy in the cornea. Prog Retin Eye Res 2005; 24: 537-59.
6. Kochanek S, Schiedner G, Volpers C. High-capacity 'gutless' adenoviral vectors. Curr Opin Mol Ther 2001; 3: 454-63.
7. Alba R, Bosch A, Chillon M. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 2005; 12: S18-S27.
8. Draper SJ, Moore AC, Goodman AL, et al. Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 2008; 14: 819-21.
9. Jager L, Ehrhardt A. Emerging adenoviral vectors for stable correction of genetic disorders. Curr Gene Ther 2007; 7: 272-83.
10. Budenz DL, Bennett J, Alonso L, Maguire A. In vivo gene transfer into murine corneal endothelial and trabecular meshwork cells. Invest Ophthalmol Vis Sci 1995; 36: 2211-5.
11. Qian Y, Leong FL, Kazlauskas A, Dana MR. Ex vivo adenovirus-mediated gene transfer to corneal graft endothelial cells in mice. Invest Ophthalmol Vis Sci 2004; 45: 2187-93.
12. Beutelspacher SC, Serbecic N, Tan P, McClure MO. Comparison of several viral vectors for gene therapy of corneal endothelial cells. Ophthalmologe 2005; 102: 1168-74.
13. Fehervari Z, Rayner SA, Oral HB, George AJ, Larkin DF. Gene transfer to ex vivo stored corneas. Cornea 1997; 16: 459-64.
14. Ritter T, Vogt K, Rieck P, et al. Adenovirus-mediated gene transfer of interleukin-4 to corneal endothelial cells and organ cultured corneas leads to high IL-4 expression. Exp Eye Res 1999; 69: 563-8.
15. Lai CM, Brankov M, Zaknich T, et al. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther 2001; 12: 1299-310.
16. Comer RM, King WJ, Ardjomand N, Theoharis S, George AJ, Larkin DF. Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival. Invest Ophthalmol Vis Sci 2002; 43: 1095-103.
17. Jessup CF, Brereton HM, Sykes PJ, Thiel MA, Coster DJ, Williams KA. Local gene transfer to modulate rat corneal allograft rejection. Invest Ophthalmol Vis Sci 2005; 46: 1675-81.
18. Gong N, Pleyer U, Yang J, et al. Influence of local and systemic CTLA4Ig gene transfer on corneal allograft survival. J Gene Med 2006; 8: 459-67.
19. Gong N, Pleyer U, Volk HD, Ritter T. Effects of local and systemic viral interleukin-10 gene transfer on corneal allograft survival. Gene Ther 2007; 14: 484-90.
20. Gong N, Pleyer U, Vogt K, et al. Local overexpression of nerve growth factor in rat corneal transplants improves allograft survival. Invest Ophthalmol Vis Sci 2007b; 48: 1043-52.
21. Larkin DF, Oral HB, Ring CJ, Lemoine NR, George AJ. Adenovirus-mediated gene delivery to the corneal endothelium. Transplantation 1996; 61: 363-70.
22. Rayner SA, Larkin DF, George AJ. TNF receptor secretion after ex vivo adenoviral gene transfer to cornea and effect on in vivo graft survival. Invest Ophthalmol Vis Sci 2001; 42: 1568-73.
23. Klebe S, Sykes PJ, Coster DJ, Bloom DC, Williams KA. Gene transfer to ovine corneal endothelium. Clin Exp Ophthalmol 2001; 29: 316-22.
24. Klebe S, Sykes PJ, Coster DJ, Krishnan R, Williams KA. Prolongation of sheep corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10. Transplantation 2001; 71: 1214-20.
25. Klebe S, Coster DJ, Sykes PJ, et al. Prolongation of sheep corneal allograft survival by transfer of the gene encoding ovine IL-12-p40 but not IL-4 to donor corneal endothelium. J Immunol 2005; 175: 2219-26.
26. Thiel MA, Saydam C, Pavlovic J, Hemmi S. Effect of ex vivo gene transfer with an adenoviral vector on human eye bank corneas. Ophthalmic Res 2005; 37: 67-71.
27. Oral HB, Larkin DF, Fehervari Z, et al. Ex vivo adenovirusmediated gene transfer and immunomodulatory protein production in human cornea. Gene Ther 1997; 4: 639-47.
28. Bertelmann E, Ritter T, Vogt K, Reszka R, Hartmann C, Pleyer U. Efficiency of cytokine gene transfer in corneal endothelial cells and organ-cultured corneas mediated by liposomal vehicles and recombinant adenovirus. Ophthalmic Res 2003; 35: 117-24.
29. Inoki T, Endo H, Inoki Y, et al. Damaged DNA-binding protein 2 accelerates UV-damaged DNA repair in human corneal endothelium. Exp Eye Res 2004; 79: 367-76.
30. Jessup CF, Brereton HM, Coster DJ, Williams KA. In vitro adenovirus mediated gene transfer to the human cornea. Br J Ophthalmol 2005; 89: 658-61.
31. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003; 3: 879-89.
32. Ritter T, Gong N, Pleyer U. Is ex vivo adenovirus mediated gene transfer a therapeutic option for the treatment of corneal diseases? Br J Ophthalmol 2005; 89: 648-9.
33. Büning H, Perabo L, Coutelle O, Quadt-Humme S, Hallek M. Recent developments in adeno-associated virus vector technology. J Gene Med 2008; 10: 717-33.
34. Miller DG, Petek LM, Russell DW. Adeno-associated virus vectors integrate at chromosome breakage sites. Nat Genet 2004; 36: 767-73.
35. McCarty DM, Young SM, Jr., Samulski RJ. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 2004; 38: 819-45.
36. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999; 6: 1574-83.
37. Dinculescu A, Glushakova L, Min SH, Hauswirth WW. Adeno-associated virus-vectored gene therapy for retinal disease. Hum Gene Ther 2005; 16: 649-63.
38. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 35: 2231-9.
39. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358: 2240-8.
40. Hudde T, Rayner SA, De Alwis M, et al. Adeno-associated and herpes simplex viruses as vectors for gene transfer to the corneal endothelium. Cornea 2000; 19: 369-73.
41. Tsai ML, Chen SL, Chou PI, Wen LY, Tsai RJ, Tsao YP. Inducible adeno-associated virus vector-delivered transgene expression in corneal endothelium. Invest Ophthalmol Vis Sci 2002; 43: 751-57.
42. Lai YK, Shen WY, Brankov M, Lai CM, Constable IJ, Rakoczy PE. Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther 2002; 9: 804-13.
43. Lai L, Lin K, Foulks G, Ma L, Xiao X, Chen K. Highly efficient ex vivo gene delivery into human corneal endothelial cells by recombinant adeno-associated virus. Curr Eye Res 2005; 30: 213-9.
44. Buchschacher GL. Introduction to retroviruses and retroviral vectors. Somat Cell Mol Genet 2001; 26: 1-11.
45. Naldini L, Blomer U, Gallay P et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-7.
46. Buchschacher GL Jr, Wong-Staal F. Development of lentiviral vectors for gene therapy for human diseases. Blood 2000; 95: 2499-504.
47. Vigna E, Naldini L. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000; 2(5): 308-16.
48. Anson DS, Fuller M. Rational development of a HIV-1 gene therapy vector. J Gene Med 2003; 5: 829-38.
49. Lusso P. HIV and the chemokine system: 10 years later. EMBO J 2006; 25: 447-56.
50. Kafri T. Gene delivery by lentivirus vectors an overview. Methods Mol Biol 2004; 246: 367-90.
51. Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93: 11382-8.
52. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997; 17: 314-7.
53. Miyoshi H, Takahashi M, Gage FH, Verma IM. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci USA 1997; 94: 10319-23.
54. Douglas J, Kelly P, Evans JT, Garcia JV. Efficient transduction of human lymphocytes and CD34+ cells via human immunodeficiency virus-based gene transfer vectors. Hum Gene Ther 1999; 10: 935-45.
55. Fleury S, Simeoni E, Zuppinger C, et al. Multiply attenuated, self-inactivating lentiviral vectors efficiently deliver and express genes for extended periods of time in adult rat cardiomyocytes in vivo. Circulation 2003; 107: 2375-82.
56. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
57. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-71.
58. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J Virol 1998; 72: 8150-7.
59. Delenda C. Lentiviral vectors: optimization of packaging, transduction and gene expression. J Gene Med 2004; 6 Suppl 1: S125-138.
60. Kotsopoulou E, Kim VN, Kingsman AJ, Kingsman SM, Mitrophanous KA. A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gagpol gene. J Virol 2000; 74: 4839-52.
61. Cockrell AS, Kafri T. Gene delivery by lentivirus vectors. Mol Biotechnol 2007; 36: 184-204.
62. Weber EL, Cannon PM. Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential. Hum Gene Ther 2007; 18: 849-60.
63. Yáñez-Muñoz RJ, Balaggan KS, MacNeil A, et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006; 12: 348-53.
64. Philpott NJ, Thrasher AJ. Use of nonintegrating lentiviral vectors for gene therapy. Hum Gene Ther 2007; 18: 483-9.
65. Poeschla EM. Non-primate lentiviral vectors. Curr Opin Mol Ther 2003; 5: 529-40.
66. Saenz DT, Poeschla EM. FIV: from lentivirus to lentivector. J Gene Med 2004; 6 (Suppl 1): S95-104.
67. Bainbridge JW, Stephens C, Parsley K, et al. In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium. Gene Ther 2001; 8: 1665-8.
68. Derksen TA, Sauter SL, Davidson BL. Feline immunodeficiency virus vectors. Gene transfer to mouse retina following intravitreal injection. J Gene Med 2002; 4: 463-9.
69. Takahashi K, Luo T, Saishin Y, et al. Sustained transduction of ocular cells with a bovine immunodeficiency viral vector. Hum Gene Ther 2002; 13: 1305-16.
70. Beutelspacher SC, Serbecic N, Tan P, McClure MO. Comparison of several viral vectors for gene therapy of corneal endothelial cells. Ophthalmologe 2005; 102: 1168-74.
71. Balaggan KS, Binley K, Esapa M, et al. Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors. J Gene Med 2006; 8: 275-85.
72. Barcia RN, Dana MR, Kazlauskas A. Corneal graft rejection is accompanied by apoptosis of the endothelium and is prevented by gene therapy with Bcl-xL. Am J Transplant 2007; 7: 2082-9.
73. Challa P, Luna C, Liton PB, et al. Lentiviral mediated gene delivery to the anterior chamber of rodent eyes. Mol Vis 2005; 11: 425-30.
74. Murthy RC, McFarland TJ, Yoken J, et al. Corneal transduction to inhibit angiogenesis and graft failure. Invest Ophthalmol Vis Sci 2003; 44: 1837-42.
75. Beutelspacher SC, Ardjomand N, Tan PH, et al. Comparison of HIV-1 and EIAV-based lentiviral vectors in corneal transduction. Exp Eye Res 2005; 80: 787-94.
76. Wang X, Appukuttan B, Ott S, et al. Efficient and sustained transgene expression in human corneal cells mediated by a lentiviral vector. Gene Ther 2000; 7: 196-200.
77. Suh LH, Zhang C, Chuck RS, et al. Cryopreservation and lentiviral-mediated genetic modification of human primary cultured corneal endothelial cells. Invest Ophthalmol Vis Sci 2007; 48: 3056-61.
78. Parker DGA, Kaufmann C, Brereton HM, et al. Lentivirus-mediated gene transfer to the rat, ovine and human cornea. Gene Ther 2007; 14: 760-7.
79. Bennett J. Immune response following intraocular delivery of recombinant viral vectors. Gene Ther 2003; 10: 977-82
80. Follenzi A, Santambrogio L, Annoni A. Immune responses to lentiviral vectors. Curr Gene Ther 2007; 7: 306-15.
81. Brown BD, Sitia G, Annoni A, et al. In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood 2007; 109: 2797-805.
82. McConnell MJ, Imperiale MJ. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 2004; 15: 1022-33.
83. Volpers C, Kochanek S. Adenoviral vectors for gene transfer and therapy. J Gene Med 2004; 6 (Suppl 1): S164-171.
84. Le Doux JM, Davis HE, Morgan JR, Yarmush ML. Kinetics of retrovirus production and decay. Biotechnol Bioeng 1999; 63: 654-62.
85. Fleury S, Simeoni E, Zuppinger C, et al. Multiply attenuated, self-inactivating lentiviral vectors efficiently deliver and express genes for extended periods of time in adult rat cardiomyocytes in vivo. Circulation 2003; 107: 2375-82.
86. Liu JW, Pernod G, Dunoyer-Geindre S, et al. Promoter dependence of transgene expression by lentivirus-transduced human blood-derived endothelial progenitor cells. Stem Cells 2006; 24: 199-208.
87. Brooks AR, Harkins RN, Wang P, Qian HS, Liu P, Rubanyi GM. Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med 2004; 6: 395-404.
88. Weber EL, Cannon PM. Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential. Hum Gene Ther 2007; 18: 849-60.
89. Hofmann W, Schubert D, LaBonte J, et al. Species-specific, postentry barriers to primate immunodeficiency virus infection. J Virol 1999; 73: 10020-8.
90. Ikeda Y, Collins MK, Radcliffe PA, Mitrophanous KA, Takeuchi Y. Gene transduction efficiency in cells of different species by HIV and EIAV vectors. Gene Ther 2002; 9: 932-8.
91. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-9.
92. Bushman FD. Retroviral integration and human gene therapy. J Clin Invest 2007; 117: 2083-6.
93. Seitz B, Baktanian E, Gordon EM, Anderson WF, LaBree L, McDonnell PJ. Retroviral vector-mediated gene transfer into keratocytes: in vitro effects of polybrene and protamine sulfate. Graefes Arch Clin Exp Ophthalmol 1998; 236: 602-12.
94. Behrens A, Gordon EM, Li L, et al. Retroviral gene therapy vectors for prevention of excimer laser-induced corneal haze. Invest Ophthalmol Vis Sci 2002; 43: 968-77.
95. Bradshaw JJ, Obritsch WF, Cho BJ, Gregerson DS, Holland EJ. Ex vivo transduction of corneal epithelial progenitor cells using a retroviral vector. Invest Ophthalmol Vis Sci 1999; 40: 230-5.
96. Andrieu-Soler C, Bejjani R-A, de Bizemont T, Normand N, BenEzra D, Behar-Cohen F. Ocular gene therapy: a review of noviral strategies. Mol Vis 2006; 12: 1334-47.
97. Pillai RG, Beutelspacher SC, Larkin DF, George AJ. Expression of the chemokine antagonist vMIP II using a non-viral vector can prolong corneal allograft survival. Transplantation 2008; 85: 1640-7.
98. Parker AL, Collins L, Zhang X, Fabre JW. Exploration of peptide motifs for potent non-viral gene delivery highly selective for dividing cells. J Gene Med 2005; 7: 1545-54.
99. Parker AL, Eckley L, Singh S, Preece JA, Collins L, Fabre JW. (LYS)(16)-based reducible polycations provide stable polyplexes with anionic fusogenic peptides and efficient gene delivery to post mitotic cells. Biochim Biophys Acta 2007; 1770: 1331-7.
100. Muller A, Zhang EP, Schroff M, Wittig B, Hoffmann F. Influence of ballistic gene transfer on antigen-presenting cells in murine corneas. Graefes Arch Clin Exp Ophthalmol 2002; 240: 851-9.
101. Zhang EP, Franke J, Schroff M, Junghans C, Wittig B, Hoffmann F. Ballistic CTLA4 and IL-4 gene transfer into the lower lid prolongs orthotopic corneal graft survival in mice. Graefes Arch Clin Exp Ophthalmol 2003; 241: 921-6.
102. Beutelspacher SC, Pillai R, Watson MP, et al. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur J Immunol 2006; 36: 690-700.